Positive results for SGN-35 against Hodgkins lymphona announced

hodgkins-histopathology.jpg

Seattle Genetics has announced top-line results from a phase II trial of its antibody-drug conjugate (ADC) brentuximab vedotin (SGN-35) for patients with relapsed or refractory Hodgkin's lymphoma

Read more of this story at CancerTreatment.net

LymphomaInfo Social